Latest News for: her2

Edit

DESTINY-Gastric05 Phase 3 Trial of ENHERTU� Initiated in Patients with Previously Untreated HER2 Positive Advanced ...

Business Wire 31 Mar 2025
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DESTINY-Gastric05 Phase 3 Trial of ENHERTU� Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ... .
Edit

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025 (Form 8-K) (Abpro Holdings Inc)

Public Technologies 26 Mar 2025
Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema.
Edit

HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight ...

GetNews 26 Mar 2025
“" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HER2-Positive Breast Cancer Market ... HER2-Positive Breast Cancer Overview.
Edit

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x ...

Nasdaq Globe Newswire 25 Mar 2025
Abpro has a strategic partnership with Celltrion for worldwide development and commercialization of AB-102/CT-P72. Abpro has a strategic partnership with Celltrion for worldwide development and commercialization of AB-102/CT-P72 ... .
Edit

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

PR Newswire 24 Mar 2025
HeriCare-Ovarian01 is the first Phase 3 clinical trial (NCT06834672) in China to investigate PROC with HER2 expression (IHC 1+, 2+ or 3+) ... There are currently no anti-HER2 treatments approved for HER2-overexpressed ovarian cancer in China.
Edit

Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer

PR Newswire 19 Mar 2025
... allows simultaneous binding of HLX22 and trastuzumab to HER2 dimers (HER2 homodimer and HER2/EGFR heterodimer) on tumour cell surface, thereby promoting the internalization and HER2 dimer degradation.
Edit

DATROWAY® Launched in Japan as the First TROP2 Directed Therapy for Patients with Previously Treated Unresectable or Recurrent HR Positive, HER2 Negative Breast Cancer (Daiichi Sankyo Co Ltd)

Public Technologies 19 Mar 2025
DATROWAY is the first ever TROP2 directed medicine to be launched in Japan for HR positive, HER2 negative breast cancer and is the second DXd antibody drug conjugate (ADC) available based on Daiichi Sankyo's DXd ADC Technology.
  • 1
×